CURRENT RESEARCH STUDIES
Healthy Volunteers Aged 55-80
Re𝜏ain is a placebo-controlled trial evaluating whether an active immunotherapy is safe, tolerable, and effective at slowing the onset of Alzheimer’s disease in people who are at risk.
People with Mild Cognitive Impairment
COGNIKET-MCI is a placebo-controlled trial investigating whether ketones and B vitamins help cognitive function for people with Mild Cognitive Impairment.
People with Mild Cognitive Impairment or Alzheimer's disease
CLARITY-AD is a placebo-controlled trial in the Open Label Extension Phase, investigating whether drug, Lecanemab, helps slow the progression of Alzheimer’s disease.
EVOKE and EVOKE Plus are placebo-controlled trials investigating whether drug, Semaglutide, may help with cognition and daily functioning. Semaglutide is already licensed to treat Type 2 Diabetes.
PEBBAL2 is an observational study investigating how the leakiness of the blood brain barrier and inflammation might contribute to cognitive decline in Alzheimer's disease.
POLARIS-AD is a placebo-controlled trial investigating whether drug, AR1001, may help the blood vessels in the brain work better for people with Alzheimer's disease.
TRAILBLAZER5 is a placebo-controlled trial investigating whether drug, Donanemab, may help slow the progression of Alzheimer’s disease.
People with Dementia with Lewy bodies
COBALT is a placebo-controlled trial investigating whether Memantine improves health and functioning for people with Dementia with Lewy bodies. Memantine is already licensed to help treat symptoms in Alzheimer's disease.
BRIC is an observational study investigating how inflammation might play a role in cognitive problems for people with Lewy body dementia.
REWIND-LB is a placebo-controlled trial investigating whether, Neflamapimod, may help learning, memory and cognitive function for people living with Lewy body dementia.